When specialist healthcare investment company Syncona Ltd discovered the ground-breaking cell therapy research being conducted by scientists at the University of Edinburgh it sparked a collaboration that went on to fuel the launch of pioneering biotechnology spinout Resolution Therapeutics.
Biotech spinout Resolution Therapeutics has announced it has raised £63.5 million in a series B financing round led by healthcare investor Syncona Ltd.
Four University of Edinburgh-supported companies have been named in Scotland’s Top 15 Tech Startups in recent analysis by data experts Beauhurst.
A clinical trial follow-up featuring patients with end-stage liver cirrhosis shows increased survival rates and fewer liver transplants in those treated with macrophage cell therapy.
A new type of cell therapy to treat patients with liver scarring, or cirrhosis, shows promise of being the first medical treatment for this common and lethal condition.
At the University of Edinburgh it is policy to promote the commercial potential of any new ideas, discoveries or inventions arising from research, and there is an established commercialisation process for transferring them to industry through Edinburgh Innovations (EI).
Edinburgh Innovations has announced record research translation figures for the financial year 2023/24, including the launch of 127 companies, 140 patents filed and £141 million invested into University-associated companies.
The Mass Spectrometry Core is a facility equipped with state-of-the-art instrumentation for sample preparation, chromatographic separation and mass spectrometry analysis for small molecule quantitation of biomarkers and drugs.
The University’s groundbreaking work in emerging engineering biology and AI-led approaches to future health was showcased recently in Boston, USA.
Taking an engineering approach to building biological systems – engineering biology – has spectacular potential to revolutionise how we diagnose and treat disease.
Here in Scotland, we currently have a confluence of factors – data capacity, clinical and academic expertise, and technology – that put us in pole position to translate our excellent liver disease research and to develop the innovative new treatments we need, writes Dr Prakash Ramachandran, MRC Senior Clinical Fellow and Consultant Hepatologist at the University of Edinburgh...
